Home›Companies›Biotech & Pharma›Myrtelle

Myrtelle Inc.

Develops gene therapies for people with neurological diseases.

Updated Nov 10, 2026·Latest SEC filing Jul 2, 2026·Suggest an edit

About Myrtelle

Myrtelle is a private company based in New York, New York, incorporated in 2021 in Delaware. It has reported $89,940,753 raised in six offerings on Form D since June 2021. Its chief executive is Adrian Stecyk.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 22, 2026Jul 2, 2026$16,700,000of $30.0M target3$5.5MDebt, Options, Securities on exerciseRule 506(b)Form D ↗
Dec 11, 2025Dec 23, 2025$30,531,749of $55.1M target21$1.4MEquity, Exchanging Convertible Notes for Series B-2 Preferred StockRule 506(b)Form D ↗
Mar 12, 2025Mar 21, 2025$7,485,000of $15.0M target1$7.4MDebtRule 506(b)Form D ↗
May 21, 2024Jun 10, 2024$6,040,000of $10.0M target11$549KDebtRule 506(b)Form D ↗
Oct 4, 2022Oct 17, 2022$15,684,004of $30.0M target6$2.6MEquity, Securities on exerciseRule 506(b)Form D ↗
Apr 26, 2021Jun 24, 2021amended Jul 8, 2021$13,500,000of $20.5M target27$500KEquityRule 506(b)Form D/A ↗1 earlier filing
Total, six offerings$89,940,753

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Myrtelle's Form D filed Jul 2, 2026.

LP
AS
Adrian Stecyk
Chief Executive Officer and director
MM
Michael Muhonen
Co-Chief Medical Officer and director
DY
Debra Yu
Director
TB

Earlier filings also listed Fay Xing (director, last listed Mar 2025), Mark Pykett (chief executive officer and director, last listed Oct 2022) and James Huang (director, last listed Oct 2022).

Sources

  1. SECMyrtelle Inc. Form D, filed Jun 24, 2021
  2. SECMyrtelle Inc. filing history
  3. CompanyAbout Myrtelle
  4. CompanyMyrtelle team
  5. CompanyPrivacy policy